Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

Undiagnosed Non-Valvular Atrial Fibrillation:
A Pharmacist’s Guide to Improving Identification and Management for Stroke Prevention (Webinar)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb and the Pfizer Alliance.

Registration & Dates for Activities

Tuesday, December 7, 2021
1:00 - 2:30 PM ET Tuesday, December 14, 2021
3:00 – 4:30 PM ET

Faculty

Brian T. Cryder, PharmD, BCACP
Associate Professor of Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove, IL
Clinical Pharmacists
Advocate Medical Group
Chicago, IL

ACCREDITATION STATEMENTS

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-21-088-L01-P
Credits: 1.5 hours (0.15 ceu)
Estimated time to complete activity: 90 minutes

Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information: There is no fee for this educational activity.
Type of Activity: Application
Media: Internet

TARGET AUDIENCE

Health-system pharmacists and other pharmacists who may manage patients with undiagnosed Non-Valvular Atrial Fibrillation (NVAF).

HOW TO EARN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.

Goal

To educate health-system pharmacists on the burden and consequences of undiagnosed and untreated Non-Valvular Atrial Fibrillation (NVAF), improve the identification of undiagnosed NVAF, and effectively manage patients with NVAF in order to reduce the risk of preventable stroke.

LEARNING OBJECTIVES

Upon completion of this activity, the participant should be better able to:

• Explain the implications of undiagnosed/untreated NVAF and discuss the various types of screening methods for AF
• Discuss principles of stroke prevention in newly diagnosed NVAF
• Compare pharmacological characteristics, efficacy, and safety profiles of oral anticoagulants used for stroke prevention in NVAF
• Formulate individualized, evidence-based anticoagulation plans for newly diagnosed/previously untreated patients with NVAF using a shared decision-making process

Agenda

Introduction (5 minutes)
Presentation (75 minutes)
Conclusions & Question & Answer Session (10 minutes)

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5